八十岁以上肌层浸润性膀胱癌患者的治疗模式与总生存结局:国家癌症数据库分析
基于国家癌症数据库分析2004至2013年确诊的80岁以上肌层浸润性膀胱癌(cT2-T4aN0M0)患者共9270例,中位随访12.8个月。根治性膀胱切除术后化疗组中位总生存34.5个月,优于放化疗组与单纯根治性膀胱切除术组。放化疗与单纯根治性膀胱切除术生存无统计学差异,且均优于单纯化疗或单纯放疗。
要点
- 根治性膀胱切除术联合化疗组中位总生存34.5个月,为各组最长。
- 放化疗组中位总生存27.3个月,与单纯根治性膀胱切除术无统计学差异。
- 单纯根治性膀胱切除术中位总生存23.2个月,优于单纯化疗或单纯放疗。
核心结论
- 在老年肌层浸润性膀胱癌患者中,放化疗是一种替代性根治治疗策略,其生存与单纯手术相当,且优于单纯化疗或单纯放疗。
- 若患者能够接受手术联合新辅助或辅助化疗,在此非随机研究中观察到额外的生存获益。
研究设计与样本
- 基于国家癌症数据库的注册分析,纳入2004至2013年确诊的80岁及以上肌层浸润性(cT2-T4aN0M0)膀胱癌患者共9270例,中位随访12.8个月。
- 患者接受的治疗包括经尿道膀胱肿瘤电切术后根治性膀胱切除术、根治性膀胱切除术联合化疗、单纯放疗、单纯化疗、放化疗或未治疗。
- 采用Kaplan-Meier法、对数秩检验、多因素Cox比例风险回归和倾向性评分匹配进行分析。
主要发现
- 单纯根治性膀胱切除术组中位总生存23.2个月(95%CI 19.8-26.6),优于单纯化疗或单纯放疗(p<0.0001)。
- 放化疗组中位总生存27.3个月(95%CI 25.0-29.7),与单纯根治性膀胱切除术无统计学差异(p=0.39)。
- 手术联合化疗组中位总生存34.5个月(95%CI 22.2-46.7),与放化疗组和单纯根治性膀胱切除术组相比p<0.0001。
- 多因素分析和倾向性评分匹配显示,手术联合化疗组总生存最佳,放化疗与单纯根治性膀胱切除术之间总生存无差异。
临床怎么用
- 作者结论认为,对于老年肌层浸润性膀胱癌患者,放化疗是一种替代性根治治疗策略,其生存与单纯手术相当,且优于单纯化疗或单纯放疗。
- 作者指出,若患者能够接受手术联合新辅助或辅助化疗,在此非随机研究中观察到额外的生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Elderly patients with muscle invasive bladder cancer can pose a therapeutic dilemma, given multiple comorbidities which may preclude surgery. In this registry based analysis we investigated treatment patterns and survival outcomes in this group of patients. MATERIALS AND METHODS: We queried the National Cancer Database for muscle invasive (cT2-T4aN0M0) bladder cancer in patients 80 years old or older who were diagnosed from 2004 to 2013. Patients included in study underwent transurethral resection of bladder tumor followed by radical cystectomy, radical cystectomy plus chemotherapy, radiation therapy alone, chemotherapy alone, chemoradiation or no treatment. We performed Kaplan-Meier, log rank and multivariate Cox proportional hazards regression and propensity score matching. RESULTS: A total of 9,270 patients were identified with a median followup of 12.8 months. Median overall survival in patients treated with radical cystectomy alone was 23.2 months (95% CI 19.8-26.6), which was superior to that of chemotherapy alone or radiation therapy alone (p <0.0001). Those treated with chemoradiation had a median overall survival of 27.3 months (95% CI 25.0-29.7), which did not statistically differ from that of radical cystectomy alone (p = 0.39). Surgery plus chemotherapy showed the longest median overall survival of 34.5 months (95% CI 22.2-46.7, vs chemoradiation and radical cystectomy alone p <0.0001). On multivariate analysis and propensity score matching the best overall survival was seen in patients treated with surgery plus chemotherapy and there was no difference in overall survival between chemoradiation and radical cystectomy alone. CONCLUSIONS: In elderly patients with muscle invasive bladder cancer chemoradiation is an alternative definitive treatment strategy with survival equal to that of surgery alone and superior to that of chemotherapy alone or radiation therapy alone. If a patient was able to receive neoadjuvant or adjuvant chemotherapy with surgery, additional survival was observed in this nonrandomized study.
引用
- Fischer-Valuck BW, Rao YJ, Rudra S, et al. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. J Urol. 2017. PMID: 28842247. doi:10.1016/j.juro.2017.08.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。